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FK-506 (FK) is a novel immunosuppres-
sant isolated from Streptomyces tsuku-
baens;s (Fig 1). It is nearly 500 times more 
potent than cyclosporine (CyA) in inhibiting 
lymphocyte proliferation in mixed lympho-
cyte cultures. I In vivo. it significantly prolongs 
the graft survival in rats receiving heterotopic 
heart transplantsl and dogs receiving renal l or 
liver transplants.4 
PHYSICOCHEMICAl PROPERTIES 
FK has a unique chemical structure with a 
molecular weight of 822.05. FK is fairly lipid 
soluble and is similar to CyA in its solubility 
properties. It is poorly soluble in water and 
hexane but very soluble in methanol. chloro-
form. ethyl acetate. ether. and acetone. In the 
solid state FK is stable for at least 6 months at 
240C and 40°C. A methanolic solution of the 
drug appears to be stable for at least 4 weeks 
at - 20°C. for 2 weeks at 5°C. and about I 
week at 24°C. A methanolic solution of the 
drug decomposes into multiple components in 
presence of 6 N HCI. However. FK is stable in 
the presence of very dilute acid. 
DOSAGE FORM 
Several dosage forms of FK were used in 
our studies. The intramuscular dosage form 
contains 50 mg of the drug, 10 mg of the 
surfactant HCD·60. and 125 mg of mannitol. 
This preparation is used after the addition of a 
required amount of normal saline and sonica-
tion for 15 minutes at room temperature. The 
oral formulation is a solid dispersion of the 
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drug (20%) that is either suspended in water 
for studies in rats or filled in a soft gelatin 
capsule for studies in dogs. For intravenous 
studies. the intramuscular dosage form is 
diluted in a mixture of alcohol, Cremophor 
EL (BASF Wyandotte Corp. Parsippany, 
NJ). and normal saline. 
DRUG ANAlYSIS 
FK does not contain any chromophores. A 
methanolic solution of the drug absorbs UV 
light to the maximum extent (A",..) at 192 nm. 
The compound also does not volatilize readily 
and has no intrinsic fluorescence. Therefore. 
traditional analytic methods such as gas chro-
matography or gas chromatography-mass 
spectrometry cannot readily be used to ana. 
Iyze intact FK in biologic fluids. FK can be 
measured by high-pressure liquid chromatog. 
raphy (HPlC) or by an enzyme immunoassay 
(EIA). 
HPLC Analysis 
HPlC assay can be used for FK measure· 
ment under certain circumstances. Because a 
number of components absorb UV light at 19i 
nm. a wave length of 210 or 214 nm has to be 
used for measuring FK by HPlC. This results 
in a low sensitivity for measuring the drug in 
biologic fluids. The HPlC assay is linear over 
a concentration range of 50 to 1.000 ng/mL 
and requires at least 1 mL of the biologic 
fluid. This assay can be used to test the 
stability of the dosage form of the drug. 
£nzym~ Immunoassa.v 
I n this assay. the drug is extracted from 
biologic fluids with benzene after the addition 
of 0.2 mol/L phosphate buffered saline (PBS. 
pH 7.0). The benzene extract is reconstituted 
in a mixture of 1:4 peroxidase-FK conjugate 
(FK·POD) and 0.05% Tween 20 and 0.5% 
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Fig 1. Chemicalltructura of FK-&08. 
bovine serum albumin in PBS (T-BSA-PBS). 
Before this. 200 ~i of the polyclonal FK-
antibody solution in PBS is added to each well 
of a 96-well fiat tissue culture plate and 
incubated at 4°C overnight. The plates are 
then washed multiple times with 0.05% Tween 
20 in PBS. Approximately 300 ~i of 
T-BSA-PBS is added to all the wells and 
incubated at room temperature for two hours 
to suppress any nonspecific binding of FK-
POD to the plastic wells. The plates are 
washed with 0.05% Tween in PBS and filled 
with PBS. This solution is aspirated. the 
reconstituted extract is added to each well. 
and the plates are incubated on a plate rotor 
overnight at 4°C. The solution in the plates is 
aspirated. the substrate solution (1.0 mg/mL 
of O-phenylenediamine dihydrochloride and 
0.015% H101 in phosphate-citrate buffer. pH 
5.4) is added. and the plates are incubated at 
room temperature for 20 minutes in the dark. 
Fifty microliters of 4 N H,80. is added to 
stop the reaction of the peroxidase enzyme 
with H20} and O-phenylenediamine. The 
optical density is measured at 492 nm. The 
concentration of FK in the sample is calcu-
lated from a standard curve developed by 
using known amounts of FK. 
The mmimum detectable concentration of 
FK when using EIA is 0.1 ng/mL. A standard 
curve is constructed and used over a concen-
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optical daMity at 492 nm. 
tration range of 0.1 to 100 ng/mL (Fig 2). 
Samples with a concentration of greater than 
100 ng/mL are diluted in PBS and then 
analyzed. 
PHARMACOKINETICS 
Absorption 
Oral administration. Oral absorption 
studies of FK were carried out in male beagle 
dogs eight days after daily oral administration' 
of FK in a soft gelatin capsule. Blood samples 
were obtained from the femoral vein at O. I. 2. 
3. 4. 6. 8. 10. 12. 16. and 24 hours after drug 
administration. Figure 3 shows the plasma 
concentration-olf-time profile in a dog after 
oral administration of 1 mg/kg of FK. After 
oral administration of I. 2. or 4 mg/kg of FK. 
the trough plasma concentrations were 0.48. 
1.4. and 6.8 ng/mL. respectively. There was a 
wide variation in the trough plasma concen-
trations of FK in animals receiving the same 
oral dose.<0.25 to 0.8 ng/mL after a I-mg/kg 
dose and 0.2 to 2.3 ng/mL after a 2-mg/kg 
dose). The drug was rapidly absorbed. with 
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the time for maximum blood concentration 
(t...) of one to three hours. This indicates that 
the drug is absorbed from the proximal part of 
the small intestine. However. after 4 mg/kg. 
there was prolonged absorption of the drug, 
and peak plasma concentrations were ob-
served only six to ten hours after drug admin-
istration. The specific reasons for this observa-
tion are not clear at this point but may be 
related to potential gastric motility changes 
mediated by the drug. The maximal plasma 
concentrations (emu) ranged from 0.8 to 1.8 
ng/mL after a I·mg/kg dose and from 3.2 to 
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5.3 ng/mL after a 2·mg/kg dose. When 
absorption studies were conducted on day 15 
after daily FK administration. a general ten-
dency for emu and T mu to increase was 
observed. which indicated changes in the rate 
and the extent of FK absorption with time. 
In some dogs, secondary peaks in plasma 
concentrations were observed (Fig 4). The 
specific rcason(s) for this phenomenon is not 
clear at this time. In theory, this may he due to 
enterohepatic recirculation of the drug or 
biliary excretion of a conjugated metabolite of 
the drug that is hydrolyzed in the gut and is 
reabsorbed. Precipitation of the drug due to 
tbe local environment. such as pH changes, 
and subsequent reabsorption can also be 
responsible for sucb an observation. Differen-
tial absorption from different segments of the 
gut could also contribute to secondary peaks. 
Studies in animals where bile can be diverted 
from the gut.l and further studies of the pH-
solubility profile of the drug are needed to I 
characterize this process. 
The area under the plasma concentration-· 
v-time curve (AUe) as measured on day 8 
after oral administration of 1. 2. or 4 mg/kg of 
FK is shown in Fig 5. This figure indicates a 
disproportionate increase in AUe with a 
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small increase in the dose. This may be due to 
saturation of the drug-metabolizing enzymes 
responsible for FK elimination. saturation of 
the tissue uptake of the drug, or prolonged or 
sustained presence of the drug at the site of 
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absorption. thereby increasing the fraction of 
the dose that is absorbed after a 4-mg/kg 
dose. 
Intramuscular administration. FK was 
administered intramuscularly (0.49 mg/kg) 
into the thigh muscle of two male beagle dogs. 
Blood samples were obtained at O. I. 2. 3. 4. 6 • 
8. 12. 16. and 24 hours after drug administra-
tion. FK was slowly absorbed from the injec. 
tion site. as indicated by a slow and continuous 
increase in the plasma concentration of the 
drug over the entire study period in both dogs 
(Fig 6). 
Distribution 
Preliminary studies indicate that FK is 
distributed into RBCs. FK. however. does not 
alter the uptake of CyA by human RBCs. 
This is indicated by a blood-ta-plasma ratio of 
1.5 for Cy A in the presence of 500 ngi mL of 
FK and in the absence of FK. Studies are 
currently under way to examine the binding of 
FK to various components of blood and to 
tissucs. 
Elimination 
Studies have been carried out in rats and 
dogs after various routes of administration to 
determine the urinary excretion of FK. Inde· 
pendent of the route of administration. less 
than I % of the dose of the drug appears in the 
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urine. as determined by HPLC or EIA in both 
species over a 48-hour time period. This obser-
vation suggests that the drug is extensively 
metabolized in the body before elimination. 
After intramuscular administration in dogs 
(0.49 mg/kg). less than I % of the drug is 
excreted in the bile and urine. These observa-
tions indicate that the kinetics of FK arc not 
likely to be altered in renal impairment. How-
ever. impairment in liver function is likely to 
result in drug accumulation. thereby necessi-
tating adjustments in the FK dosing regimen. 
The half·life of FK ranges from 4.4 to 8.0 
hours. with a mean of 6.1 hours. 
The metabolic fate of FK has not yet been 
characterized. The drug may undergo hydro-
lytic cleavage and may also be conjugated and 
demethylated. If the drug is conjugated and 
the conjugate is excreted in the bile. there is a 
potential for enterohepatic recirculation of the 
drug. This may explain the secondary peaks 
observed in the plasma concentration-v-time 
curves in dogs after FK administration. 
Drug InUraCl;on 
Because immunosuppressants arc com-
monly used in combination. drug interactions 
are of major concern in transplant patients. 
Although CyA has been reported to inhibit 
drug-metabolizing enzyme systems.6 steroids 
arc known to induce the hepatic mixed-
function oxidases.1 We studied the effcct of 
FK on drug-metabolizing enzyme systems. 
Male Wistar rats weighing between 230 
and 250 g were used in this study. The animals 
were treated with placebo or 0.12 or 1.2 
mg/kg of FK intramuscularly for 14 days. On 
day 15. the animals were anesthetized by 
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ether. and the livers were excised and washed 
with Tris-KCl buffer (0.02 mol/L Tris·KCI 
buffer. pH 7.4. 1.15% KCI). Approximately 4 
g of the liver was homogenized in 2 vol of 
Tris-KCI buffer in a polytron homogenizer. 
and microsomes were prepared according to 
standard techniques. The protein a:mtent of 
the microsomes were determined bv the biuret 
methodS with BSA as the standard. Cyto-
chrome P·450 and Cytochrome b5 contents of 
the microsomal suspensions were determined 
by the method of Omura and Sato.' NADPH 
cytochrome c reductase activity was deter· 
mined by the method of Phillips and Lang-
deniO as modified by Gigon et al.II The 
N-demethylation of ethylmorphine (5 mmol/ 
L) was determined in an incubation mixture 
consisting of 5 mmol/L MgCI2, 0.43 mmol/L 
NADP. 10 mmol/L glucose-6-phosphate. 1.5 
enzyme units of g!ucose-6-phosphate deby· 
drogenase. 50 mmol/L Tris-HCI (pH 7.4), 
and 2 mg of microsomal protein according to 
the method of Nash.1l 
Table I summarizes the result of this study. 
At a dose of 0.128 mg/kg of FK. there is a 
significant decrease in the activity of ethyl· 
morphine N·demethylase activity. At a dose 
of 1.28 mg/kg, in addition to ethylmorphine 
N-dcmethylase activity, cytochrome P-450 
and cytochrome c reductase activity was also 
decreased. This indicates that fK has a dose· 
dependent effect on different components of 
the hepatic mixed·function oxidase system. 
CyA also similarly affects the mixcd·funciion 
oxidase system in the Iiver.6 Thesc observa· 
tions suggest that the elimination of coadmin-
istered drugs may be altered in the presence of 
FR. Therefore. dosage adjustment of other 
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drugs may be Qecessary. On the other hand. 
lower doses of other drugs may be effective in 
patients who receive FK, and this may result 
in some cost saving. 
SUMMARY 
FK is a potent im~unosuppressive agent. 
fK can be analyzed in biologic fluids by EIA. 
The oral absorption of FK is rapid but vari-
35 
able in dogs. After intramuscular administra-
tion. FK is slowly and continuously absorbed. 
FK is primarily eliminated by metabolism. 
Less than I % of the administered dose is 
excreted in the bile or the urine. After chronic 
intramuscular administration FK inhibits 
drug metabolism. Monitoring of FK levels in 
plasma is essential for the proper interpreta-
tion of efficacy and toxicity studies. 
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